<unk> , sold under the brand name Rinvoq, is a Janus kinase (JAK) inhibitor medication for the treatment of moderately to severely active rheumatoid arthritis and psoriatic arthritis in adults where methotrexate (a drug used to treat active arthritis) did not work well or could not be tolerated. It was approved for medical use in the United States and in the European Union in 2019, and was developed by the biotech company AbbVie. Common side effects include upper respiratory tract infections (common cold, sinus infections), nausea, cough, and fever.<unk>  works by blocking the action of enzymes called Janus kinases. These enzymes are involved in setting up processes that lead to inflammation, and blocking their effect brings inflammation in the joints under control.
Upadacitinib
Abrocitinib
Selpercatinib
Baricitinib
Erdafitinib
Oclacitinib
Dacomitinib
Axitinib